Lumos Pharma, Inc. - LUMO STOCK NEWS

Lumos Pharma (NASDAQ: LUMO) announced a share repurchase program worth up to $3 million. This decision aims to enhance shareholder value and is backed by the company's solid cash position of approximately $79.5 million as of June 30, 2022. The program allows the company to buy back its shares on the open market or through private transactions, contingent on market conditions. The CEO expressed confidence in the growth potential of Lumos Pharma, especially with key clinical data milestones expected in Q4 2022 and mid-2023.

Lumos Pharma reported its financial results for Q2 2022, ending with cash and cash equivalents of $79.5 million, down from $94.8 million at year-end 2021. The company projects a cash burn of $8.5 to $9.5 million per quarter, supporting operations through Q2 2024. Interim data from the Phase 2 OraGrowtH210 and OraGrowtH212 Trials are anticipated in Q4 2022, with primary outcome data expected in H2 2023, involving 80 subjects. R&D expenses increased to $4.6 million, while G&A expenses decreased to $3.7 million, contributing to a net loss of $7.8 million for the quarter.

Lumos Pharma, Inc. (NASDAQ:LUMO) will announce its second quarter 2022 financial results after the market closes on August 9, 2022. A conference call and webcast will follow at 4:30 PM ET to discuss the results and provide updates on clinical developments, including the evaluation of its lead candidate LUM-201 for Pediatric Growth Hormone Deficiency in ongoing Phase 2 trials. The company has received Orphan Drug Designation for LUM-201 in both the U.S. and EU, enhancing its potential market position.

Lumos Pharma, a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will participate in two upcoming investor conferences. The H.C. Wainwright 2022 Global Investment Conference will take place from May 23-26, with a live presentation scheduled for May 25 from 4:00 – 4:30 PM EDT. The Jefferies Healthcare Conference will follow from June 8-10, featuring a live fireside chat on June 8 at 3:30 – 3:55 PM EDT. Webcasts for both events can be accessed via the provided links. Lumos Pharma is developing LUM-201 for Pediatric Growth Hormone Deficiency, which has Orphan Drug Designation in the US and EU.

Lumos Pharma reported significant advancements in its clinical trials and FDA interactions regarding LUM-201, aimed at treating pediatric growth hormone disease. The Phase 2 OraGrowtH210 Trial surpassed the 50% randomization milestone, with interim data expected by the end of 2022. The FDA lifted its partial clinical hold, allowing LUM-201 treatment beyond 12 months. A peer-reviewed publication highlighted LUM-201's efficacy, showing it as a potent GH secretagogue. The company also initiated a collaboration with Massachusetts General Hospital to evaluate LUM-201 for Nonalcoholic Fatty Liver Disease.

Lumos Pharma's LUM-201, an oral growth hormone secretagogue, has received FDA approval for a pilot trial targeting Nonalcoholic Fatty Liver Disease (NAFLD). This Phase 2 study will evaluate the drug's efficacy in 10 adults over six months, focusing on intrahepatic lipid content and liver inflammation. The collaboration involves Massachusetts General Hospital, with the principal investigator Dr. Laura Dichtel highlighting the hormone's potential benefits. LUM-201 is already designated as an orphan drug for other uses, showcasing its promise in treating rare diseases.

Lumos Pharma, Inc. (NASDAQ:LUMO) will report its Q1 2022 financial results on May 10, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and updates on clinical and corporate activities. Investors can access the audio webcast via phone or online. Lumos Pharma focuses on developing therapeutics for rare diseases, with its lead candidate LUM-201 currently being evaluated in Phase 2 trials for Pediatric Growth Hormone Deficiency. LUM-201 has received Orphan Drug Designation in both the US and EU.

Lumos Pharma (NASDAQ: LUMO) has achieved a significant milestone by reaching 50% randomization in its Phase 2 OraGrowtH210 Trial for pediatric growth hormone deficiency (PGHD). Interim data from both the OraGrowtH210 and OraGrowtH212 Trials is expected by the end of 2022, providing insights into the efficacy and safety of oral LUM-201 compared to standard care. The OraGrowtH210 Trial is evaluating three dose levels in approximately 80 subjects, while OraGrowtH212 focuses on pharmacokinetic and pharmacodynamic effects in 24 subjects. Full primary outcome data is set for mid-2023.

Lumos Pharma (NASDAQ:LUMO) will have its President and Chief Scientific Officer, John McKew, participate in a panel at the Cantor Rare Disease Symposium from March 28-30, 2022. The panel, titled “New World Order for Endo/CV/Renal Diseases – Applying Precision Medicine”, is scheduled for March 29 at 1:00 PM (EDT). This discussion aims to address the shift from prevalent to rare diseases in precision medicine. Lumos Pharma focuses on therapeutics for rare diseases, with its lead candidate LUM-201 targeting Pediatric Growth Hormone Deficiency, currently in Phase 2 trials.